ATE83155T1 - Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. - Google Patents

Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Info

Publication number
ATE83155T1
ATE83155T1 AT88117833T AT88117833T ATE83155T1 AT E83155 T1 ATE83155 T1 AT E83155T1 AT 88117833 T AT88117833 T AT 88117833T AT 88117833 T AT88117833 T AT 88117833T AT E83155 T1 ATE83155 T1 AT E83155T1
Authority
AT
Austria
Prior art keywords
high ionic
plasma
protein formulations
recombination protein
ionic milieu
Prior art date
Application number
AT88117833T
Other languages
English (en)
Inventor
Ted C K Lee
Michael E Hrinda
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE83155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Application granted granted Critical
Publication of ATE83155T1 publication Critical patent/ATE83155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT88117833T 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. ATE83155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29
EP88117833A EP0314095B1 (de) 1987-10-29 1988-10-26 Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke

Publications (1)

Publication Number Publication Date
ATE83155T1 true ATE83155T1 (de) 1992-12-15

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88117833T ATE83155T1 (de) 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Country Status (8)

Country Link
EP (1) EP0314095B1 (de)
JP (1) JP2544968B2 (de)
AT (1) ATE83155T1 (de)
AU (1) AU622133B2 (de)
CA (1) CA1329760C (de)
DE (1) DE3876600T2 (de)
ES (1) ES2053676T3 (de)
GR (1) GR3006506T3 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029765T2 (de) * 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1561469A1 (de) * 1997-04-28 2005-08-10 Eli Lilly & Company Aktiviertes Protein C Formulierungen
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
ES2179414T3 (es) * 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
EP2193809B1 (de) 1999-02-22 2015-04-08 University of Connecticut Albuminfreie Faktor VIII Formulierungen
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
KR20140093711A (ko) 2003-12-19 2014-07-28 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
RU2013131911A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Водный раствор фактора viii
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
JP2015527350A (ja) * 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
EP3370695A1 (de) * 2015-11-05 2018-09-12 Novo Nordisk A/S Fviii-formulierung
EP3694322B1 (de) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilisierungsbehälter und verfahren zu seiner verwendung
EP3938741B1 (de) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilisierungsbehälterfüllvorrichtung, system und verfahren zur verwendung
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
JPH01149733A (ja) 1989-06-12
JP2544968B2 (ja) 1996-10-16
EP0314095A1 (de) 1989-05-03
AU622133B2 (en) 1992-04-02
DE3876600D1 (de) 1993-01-21
EP0314095B1 (de) 1992-12-09
CA1329760C (en) 1994-05-24
AU2452088A (en) 1989-05-04
ES2053676T3 (es) 1994-08-01
GR3006506T3 (de) 1993-06-30
DE3876600T2 (de) 1993-04-15

Similar Documents

Publication Publication Date Title
ATE83155T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
ATE76304T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.
ATE198143T1 (de) Zahnpasten
FI873364A0 (fi) Foerfarande foer framstaellning av ett sytotoxiskt laekemedel.
DE69519580D1 (de) Zahnpflegemitteln
DK183386A (da) Sucralfatsuspension
NO933455L (no) Bis-naftalimider som inneholder aminosyreavledete linkere, for anvendelse som antikreftmidler
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
MX9301450A (es) Recipiente con gases comprimidos para la utilizacion de polioxietilen-gliceril-oleatos
DK0378262T3 (da) Flydende detergentsammensætning indeholdende et enzym og et enzymstabiliseringssystem
NO921256D0 (no) Aminosyre-beta-lyaseenzyminhibitor som deodoranter
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DE69432899D1 (de) Flüssige ionische Zusammensetzungen verwendende Ionenpunktquellen hoher Luminosität
ITRM920734A0 (it) Composizioni per la stabilizzazione dei polimeri. (caso 153-5550)
BR8901275A (pt) Composicao detergente aquosa,abrasiva,homogenea,despejavel
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
IT213814Z2 (it) Sega meccanica da traforo.
IT213815Z2 (it) Sega meccanica da traforo.
NO901452D0 (no) Blandinger inneholdende 2-tiocyano-metyltio-benzotiazol for anvendelse som industrielle mikrobiocider.
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
BG40952A3 (en) Herbicide means
FI935342A0 (fi) Menetelmä stabiilisuudeltaan parempien natriumperkarbonaattipartikkelien valmistamiseksi
IT1175939B (it) Stabilizzatore di fascio luiminoso
RU2005177C1 (ru) Горный комбайн
BG42351A3 (bg) Средство за регулиране растежа на растения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time